p38 慢性阻塞性肺病病原和抑制剂治疗中的MAPK信号
Ali Ahmadi1, Sajjad Ahrari2, Jafar Salimian3
1Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Cell communication and signaling : CCS
|November 3, 2023
概括
在慢性阻塞性肺病 (COPD) 的发展中,p38信号传递起着作用. 虽然p38 MAPK抑制剂单独显示出有限的疗效,但将它们与类固醇结合起来可能为COPD患者提供了一个有前途的治疗策略.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性阻塞性肺病 (COPD) 涉及到气道改造和空气流量限制.
- 免疫反应在很大程度上对COPD的发病和进展作出了贡献.
- p38异型是免疫和炎症反应的关键调节者.
研究的目的:
- 系统地审查慢性阻塞性肺病 (COPD) 中p38信号的研究.
- 评估针对COPD中p38信号的治疗潜力.
主要方法:
- 在PubMed和Google Scholar上使用PRISMA指南进行系统的文献搜索.
- 包括人类,动物,ex vivo和体外研究,重点关注p38在COPD中的信号传递.
- 提取与p38信号相关的研究设计,干预措施,结果和发现的数据.
主要成果:
- p38 MAPK抑制在COPD中显示出一些治疗潜力,但有效性有限.
- 临床试验在改善肺功能和减少恶化方面产生了不同的结果.
- 与p38 MAPK抑制剂和抗炎类固醇的联合治疗似乎很有希望.
结论:
- 向p38 MAPK仍然是研究新型COPD疗法的一个活跃领域.
- 进一步了解COPD的发病因子可能会优化p38 MAPK抑制剂的使用.
- 组合策略为改善COPD治疗提供了潜在的途径.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:20COPD: Pathogenesis and Clinical Features
302
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
302
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
455
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
455
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
177
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
177